AARDVARK THERAPEUTICS INC

AARDNASDAQ

🏆 #3225 by market capEarnings Aug 11US Equity

$7.18▼ $0.36 (−4.96%)

Pre-market · at close

1h—

24h▼ 5.0%

7d▼ 4.4%

14d▲ 33.5%

30d▲ 21.8%

1y▼ 28.0%

🏦Market Cap

$157M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Weak

Trading Snapshot

Day Range: $7.08 – $7.22
52-Week Range: $3.35 – $17.94
Volume: $5.83B
Avg Volume: $4.21B
Shares Outstanding: 21.9M
Next Earnings: Sep 18, 2026

Fundamentals Snapshot

Annual Revenue: $54M
Last Q Revenue: $14M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-3.21
Dividend Yield: —

Why Investors Own AARD

✓High-growth profile — revenue up +49.6% YoY with expanding US Equity exposure.
✓Healthy economics — 62% gross margin and 19% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$54M▲ +44.0% YoY

Gross Margin (TTM)

62.0%▲ +4.0% YoY

Operating Income (TTM)

$5M▲ +44.0% YoY

Free Cash Flow (TTM)

$10M▲ +44.0% YoY

About AARDVARK THERAPEUTICS INC

Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.

🦦